Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Equity to Asset 0.14
RDNT's Equity to Asset is ranked lower than
52% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. RDNT: 0.14 )
RDNT' s 10-Year Equity to Asset Range
Min: -0.89   Max: 0.14
Current: 0.14

-0.89
0.14
Interest Coverage 178.70
RDNT's Interest Coverage is ranked higher than
68% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. RDNT: 178.70 )
RDNT' s 10-Year Interest Coverage Range
Min: 0.22   Max: 178.7
Current: 178.7

0.22
178.7
F-Score: 7
Z-Score: 53.15
M-Score: -3.00
WACC vs ROIC
15.27%
1.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 20.53
RDNT's Operating margin (%) is ranked higher than
95% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. RDNT: 20.53 )
RDNT' s 10-Year Operating margin (%) Range
Min: -116.39   Max: 21.36
Current: 20.53

-116.39
21.36
Net-margin (%) 20.42
RDNT's Net-margin (%) is ranked higher than
98% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.93 vs. RDNT: 20.42 )
RDNT' s 10-Year Net-margin (%) Range
Min: -135.47   Max: 21.2
Current: 20.42

-135.47
21.2
ROE (%) 403.71
RDNT's ROE (%) is ranked higher than
100% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. RDNT: 403.71 )
RDNT' s 10-Year ROE (%) Range
Min: 403.71   Max: 403.71
Current: 403.71

ROA (%) 2.32
RDNT's ROA (%) is ranked higher than
78% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. RDNT: 2.32 )
RDNT' s 10-Year ROA (%) Range
Min: -39.36   Max: 27.35
Current: 2.32

-39.36
27.35
ROC (Joel Greenblatt) (%) 5.40
RDNT's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.09 vs. RDNT: 5.40 )
RDNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -44.17   Max: 40.53
Current: 5.4

-44.17
40.53
Revenue Growth (3Y)(%) -56.90
RDNT's Revenue Growth (3Y)(%) is ranked higher than
52% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. RDNT: -56.90 )
RDNT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -56.9   Max: 25.5
Current: -56.9

-56.9
25.5
EBITDA Growth (3Y)(%) -50.20
RDNT's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. RDNT: -50.20 )
RDNT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50.2   Max: 169.2
Current: -50.2

-50.2
169.2
EPS Growth (3Y)(%) -46.00
RDNT's EPS Growth (3Y)(%) is ranked higher than
55% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. RDNT: -46.00 )
RDNT' s 10-Year EPS Growth (3Y)(%) Range
Min: -46   Max: 28.4
Current: -46

-46
28.4
» RDNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RDNT Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

RDNT Guru Trades in Q2 2014

Jim Simons 798,900 sh (New)
Paul Tudor Jones 10,084 sh (New)
» More
Q3 2014

RDNT Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
Jim Simons 532,800 sh (-33.31%)
» More
Q4 2014

RDNT Guru Trades in Q4 2014

Jim Simons 337,200 sh (-36.71%)
» More
» Details

Insider Trades

Latest Guru Trades with RDNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 13.37
RDNT's Forward P/E is ranked higher than
97% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 13.37 )
N/A
P/B 68.00
RDNT's P/B is ranked lower than
68% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. RDNT: 68.00 )
RDNT' s 10-Year P/B Range
Min: 35.71   Max: 930
Current: 68

35.71
930
P/S 0.53
RDNT's P/S is ranked higher than
97% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. RDNT: 0.53 )
RDNT' s 10-Year P/S Range
Min: 0.07   Max: 13.88
Current: 0.53

0.07
13.88
PFCF 48.90
RDNT's PFCF is ranked higher than
75% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 48.90 )
RDNT' s 10-Year PFCF Range
Min: 0.53   Max: 209.67
Current: 48.9

0.53
209.67
POCF 23.87
RDNT's POCF is ranked higher than
84% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 23.87 )
RDNT' s 10-Year POCF Range
Min: 0.48   Max: 155
Current: 23.87

0.48
155
EV-to-EBIT 34.79
RDNT's EV-to-EBIT is ranked higher than
79% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 34.79 )
RDNT' s 10-Year EV-to-EBIT Range
Min: 5.5   Max: 81
Current: 34.79

5.5
81
Shiller P/E 35.50
RDNT's Shiller P/E is ranked higher than
86% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 35.50 )
RDNT' s 10-Year Shiller P/E Range
Min: 8.88   Max: 51.5
Current: 35.5

8.88
51.5
Current Ratio 5.44
RDNT's Current Ratio is ranked higher than
89% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. RDNT: 5.44 )
RDNT' s 10-Year Current Ratio Range
Min: 0.15   Max: 5.44
Current: 5.44

0.15
5.44
Quick Ratio 5.44
RDNT's Quick Ratio is ranked higher than
90% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. RDNT: 5.44 )
RDNT' s 10-Year Quick Ratio Range
Min: 0.15   Max: 5.44
Current: 5.44

0.15
5.44
Days Sales Outstanding 51.99
RDNT's Days Sales Outstanding is ranked higher than
84% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. RDNT: 51.99 )
RDNT' s 10-Year Days Sales Outstanding Range
Min: 51.99   Max: 128.88
Current: 51.99

51.99
128.88

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 294.00
RDNT's Price/Net Current Asset Value is ranked higher than
64% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 294.00 )
RDNT' s 10-Year Price/Net Current Asset Value Range
Min: 9.82   Max: 40.67
Current: 294

9.82
40.67
Price/Median PS Value 15.50
RDNT's Price/Median PS Value is ranked lower than
56% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. RDNT: 15.50 )
RDNT' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 14.98
Current: 15.5

0.55
14.98
Earnings Yield (Greenblatt) 2.80
RDNT's Earnings Yield (Greenblatt) is ranked higher than
73% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. RDNT: 2.80 )
RDNT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 18.2
Current: 2.8

1.2
18.2
Forward Rate of Return (Yacktman) -51.68
RDNT's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.32 vs. RDNT: -51.68 )
RDNT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -52.4   Max: 100.8
Current: -51.68

-52.4
100.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PQIA.Germany,
RadNet Inc is incorporated in Delaware and has been in business since 1985. The Company provides freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At December 31, 2012, it operated directly or indirectly through joint ventures, 250 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Diagnostic imaging involves the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy. While X-ray remains the commonly performed diagnostic imaging procedure, the growing and higher margin procedures are MRI, CT and PET. The rapid growth in PET scans is attributable to the increasing recognition of the efficacy of PET scans in the diagnosis and monitoring of cancer. The number of MRI and CT scans performed annual in the United States continues to grow due to their wider acceptance by physicians and payors, an increasing number of applications for their use and a general increase in demand due to the aging population. The Companys sales and marketing team employs a multi-pronged approach to marketing, including physician, payor and sports marketing programs. The market for diagnostic imaging services is highly competitive. The Company competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Its competitors include Alliance Healthcare Services, Inc., Diagnostic Imaging Group and several smaller regional competitors.
» More Articles for RDNT

Headlines

Articles On GuruFocus.com
Doral Financial Corp (DRL) Skyrockets with Unusual Market Activity, RadNet Inc (RDNT) Soars on Resul May 12 2014 
Weekly 3-Year Lows Highlight: FWM, FST, LAND, RDNT Jan 13 2014 
research Jun 12 2011 
research Jun 12 2011 
RadNet Inc. Reports Operating Results (10-K) Mar 11 2011 
RadNet Inc. Reports Operating Results (10-Q) Aug 09 2010 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 22,200 Shares Sep 22 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 77,800 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 69,215 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 30,785 Shares Sep 18 2009 


More From Other Websites
RadNet Adds Eight Prime Manhattan Locations to Imaging Center Holdings Apr 15 2015
RadNet Expands Its New York City Presence Through the Acquisition of New York Radiology Partners Apr 14 2015
The Zacks Analyst Blog Highlights: Caterpillar, Procter & Gamble, Horizon Pharma, RadNet and PRA... Apr 07 2015
Jobs Data Dips: 3 Healthy Picks - Analyst Blog Apr 06 2015
RadNet Surges On B. Riley Initiation Mar 26 2015
RADNET, INC. Financials Mar 21 2015
RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 17 2015
RADNET, INC. Files SEC form 10-K, Annual Report Mar 16 2015
Q4 2014 RadNet Inc Earnings Release - Before Market Open Mar 16 2015
RadNet posts 4Q profit Mar 16 2015
RadNet posts 4Q profit Mar 16 2015
RadNet Reports Fourth Quarter and Record Full Year 2014 Results and Releases 2015 Financial Guidance Mar 16 2015
RadNet's eRAD Division Awarded Tender for RIS System by Assuta Medical Center, Israel's Largest... Mar 12 2015
eRAD Announces 16 New Customers for the 4th Quarter of 2014 Mar 11 2015
RadNet Awarded Contract to Provide National Cancer Screening Services in the Sovereign Arab Country,... Mar 04 2015
RadNet and Kennedy Health System Announce the Start of their Diagnostic Imaging Joint Venture and... Mar 04 2015
RadNet Awarded Contract to Provide National Cancer Screening Services in the Sovereign Arab Country,... Mar 03 2015
RadNet, Inc. Announces Date of Its Fourth Quarter 2014 Financial Results Conference Call Mar 02 2015
Quest Diagnostics Q4 Earnings, Revenues Beat; Grow Y/Y - Analyst Blog Jan 29 2015
RadNet (RDNT): Strong Industry, Solid Earnings Estimate Revisions Dec 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK